The 2024 National Medical Insurance Catalog released today shows that three innovative drugs from Bristol-Myers Squibb have been included in the catalog, including the world's first and currently only approved cardiac myosin inhibitor Mavacamten (Maraviroc capsules) for the treatment of obstructive hypertrophic cardiomyopathy, the world's first and currently only approved oral TYK2 allosteric inhibitor Zunsemetin (deucravacitinib tablets) for the treatment of moderate to severe plaque psoriasis, and the world's first and currently only approved erythroid maturation agent Luspatercept (injection of roxadustat) for the treatment of β-thalassemia.